Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exonate Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, HUANG, GIGI GEORGIANA, who is the busiest examiner with 1 pending office action. The prosecution is focused in 1 distinct art unit. This single application represents the company's current activity, which is entirely under the review of HUANG, GIGI GEORGIANA.
The assignment of 1 distinct examiner to the 1 pending office action means there is no internal comparison available for examiner behavior within this portfolio. Strategy must be developed around the specific tendencies of HUANG, GIGI GEORGIANA within the Biotechnology & Pharmaceuticals field. The concentration in 1 distinct art unit suggests a stable procedural framework for this single pending matter.
With 1 pending office action and 1 distinct examiner, the company's prosecution is entirely centralized. This lack of diversity among examiners or art units places a high priority on the specific interactions with HUANG, GIGI GEORGIANA. Practitioners should note that the 1 distinct art unit will dictate the timelines and administrative requirements for the entirety of the current pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18603489 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | HUANG, GIGI GEORGIANA | 84d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18603489 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | HUANG, GIGI GEORGIANA | 1613 | §103DP | Non-Final OA | 84d | Pending | Mar 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial